Loading...
RAS MAPK Therapies And Expanding Trials Will Transform This Rare Cancer Specialist
AN
AnalystHighTarget
Not Invested
Community Contributor
Published
06 Jan 26
Views
25
06 Jan
US$4.25
AnalystHighTarget's Fair Value
US$20.00
78.8% undervalued intrinsic discount1Y
-44.2%7D
2.9%1Y
-44.2%7D
2.9%You can edit this narrative until Jan 7 2:10 AM. Then, changes will post as Updates.
Author's Valuation
US$2078.8% undervalued intrinsic discount
AnalystHighTarget Fair Value